Rockefeller Capital Management
FLGT icon

Rockefeller Capital Management’s Fulgent Genetics FLGT Stock Holding History

Rockefeller Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.14K Buy
512
+412
+412% +$8.94K ﹤0.01% 4079
2025
Q4 		$2.63K Hold
100
– – ﹤0.01% 4252
2025
Q3 		$2.26K Buy
+100
New +$2.06K ﹤0.01% 4064
2023
Q1 		– Sell
-2,094
Closed -$62K – 2637
2022
Q4 		$62K Sell
2,094
-54
-3% -$1.93K ﹤0.01% 2271
2022
Q3 		$81K Buy
2,148
+1,972
+1,120% +$98.9K ﹤0.01% 2106
2022
Q2 		$9K Sell
176
-160
-48% -$8.79K ﹤0.01% 3166
2022
Q1 		$20K Sell
336
-945
-74% -$62.2K ﹤0.01% 2717
2021
Q4 		$128K Buy
1,281
+18
+1% +$1.58K ﹤0.01% 1827
2021
Q3 		$113K Buy
1,263
+71
+6% +$6.45K ﹤0.01% 1806
2021
Q2 		$109K Sell
1,192
-13,225
-92% -$1.06M ﹤0.01% 1764
2021
Q1 		$1.39M Buy
14,417
+82
+0.6% +$8.46K 0.01% 685
2020
Q4 		$746K Buy
+14,335
New +$599K 0.01% 779

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Rockefeller Capital Management's FLGT Position: Q1 2026 in Review

Rockefeller Capital Management increased its Fulgent Genetics (FLGT) stake by 412% in Q1 2026, buying an estimated $8.94K and bringing the position to 512 shares worth $8.14K. The position accounts for ﹤0.01% of the portfolio, ranked #4079.

Rockefeller Capital Management first reported a position in FLGT in Q4 2020 and has held it in 12 quarters since. The position peaked at $1.39M in Q1 2021. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • Rockefeller Capital Management held 512 shares of Fulgent Genetics worth $8.14K as of Q1 2026.
  • Rockefeller Capital Management bought 412 Fulgent Genetics shares in Q1 2026, an estimated $8.94K.
  • Fulgent Genetics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4079 holding.
  • Rockefeller Capital Management first reported a position in Fulgent Genetics in Q4 2020 and has held it in 12 quarters since.
  • Rockefeller Capital Management's Fulgent Genetics position peaked at $1.39M in Q1 2021.
  • 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.